BR112017005238A2 - derivados de piridin-2(1h)-ona quinolinona como inibidores da isocitrato desidrogenase mutante - Google Patents

derivados de piridin-2(1h)-ona quinolinona como inibidores da isocitrato desidrogenase mutante

Info

Publication number
BR112017005238A2
BR112017005238A2 BR112017005238A BR112017005238A BR112017005238A2 BR 112017005238 A2 BR112017005238 A2 BR 112017005238A2 BR 112017005238 A BR112017005238 A BR 112017005238A BR 112017005238 A BR112017005238 A BR 112017005238A BR 112017005238 A2 BR112017005238 A2 BR 112017005238A2
Authority
BR
Brazil
Prior art keywords
pyridin
isocitrate dehydrogenase
dehydrogenase inhibitors
mutant isocitrate
quinolinone derivatives
Prior art date
Application number
BR112017005238A
Other languages
English (en)
Other versions
BR112017005238B1 (pt
Inventor
Campbell Ann-Marie
Ericsson Anna
R Lancia David
Gustafson Gary
Lin Jian
Andrew CARAVELLA Justin
Bruce Diebold R
Ashwell Susan
Lu Wei
Wang Zhongguo
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of BR112017005238A2 publication Critical patent/BR112017005238A2/pt
Publication of BR112017005238B1 publication Critical patent/BR112017005238B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a invenção refere-se a inibidores das proteínas isocitrato desidrogenase mutantes (mt-idh) com atividade neomórfica útil no tratamento de distúrbios de proliferação celular e cânceres, tendo a fórmula: (i), em que a, u, w1, w2, w3, r1-r6 e r9 são descritos neste documento.
BR112017005238-5A 2014-09-19 2015-09-18 Derivados de piridin-2(1h)-ona quinolinona, seu uso e composição farmacêutica BR112017005238B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US62/053,006 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US62/128,089 2015-03-04
US201562150812P 2015-04-21 2015-04-21
US62/150,812 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
BR112017005238A2 true BR112017005238A2 (pt) 2017-12-19
BR112017005238B1 BR112017005238B1 (pt) 2023-01-17

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005238-5A BR112017005238B1 (pt) 2014-09-19 2015-09-18 Derivados de piridin-2(1h)-ona quinolinona, seu uso e composição farmacêutica

Country Status (36)

Country Link
US (8) US9834539B2 (pt)
EP (4) EP3194376B1 (pt)
JP (1) JP6648115B2 (pt)
KR (1) KR102209667B1 (pt)
CN (3) CN117695280A (pt)
AU (3) AU2015317329B2 (pt)
BR (1) BR112017005238B1 (pt)
CA (1) CA2961817C (pt)
CL (1) CL2017000658A1 (pt)
CO (1) CO2017003241A2 (pt)
CY (2) CY1121149T1 (pt)
DK (2) DK3447050T3 (pt)
EA (1) EA034336B1 (pt)
EC (1) ECSP17022933A (pt)
ES (3) ES2953347T3 (pt)
FI (1) FI3733662T3 (pt)
HR (1) HRP20200666T1 (pt)
HU (2) HUE062424T2 (pt)
IL (3) IL292608A (pt)
LT (2) LT3194376T (pt)
MA (2) MA40481A (pt)
ME (1) ME03776B (pt)
MX (2) MX2017003404A (pt)
MY (2) MY176250A (pt)
NZ (2) NZ758641A (pt)
PE (1) PE20171056A1 (pt)
PH (1) PH12017500517A1 (pt)
PL (3) PL3194376T3 (pt)
PT (3) PT3447050T (pt)
RS (2) RS60140B1 (pt)
SA (1) SA517381129B1 (pt)
SG (1) SG11201702194SA (pt)
SI (2) SI3194376T1 (pt)
TW (1) TWI686390B (pt)
WO (1) WO2016044789A1 (pt)
ZA (2) ZA201702127B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
RS57843B1 (sr) 2014-02-06 2018-12-31 Heptares Therapeutics Ltd Biciklična aza jedinjenja kao agonisti muskarinskog receptora m1
BR112017005444A2 (pt) 2014-09-19 2018-04-24 Bayer Pharma AG indazoles substituídos por benzil como inibidores bub1.
JP6648116B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
US9771349B2 (en) 2014-09-19 2017-09-26 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6648115B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体
CA2971872C (en) 2014-12-22 2023-10-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant idh1 inhibitors useful for treating cancer
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
ES2919280T3 (es) 2017-05-04 2022-07-22 Bayer Cropscience Ag Derivados de 2-{[2-(feniloximetil)piridin-5-il]oxi}-etanamina y compuestos relacionados como pesticidas, por ejemplo para la protección de plantas
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
EP3720442B1 (en) 2018-05-16 2022-12-28 Forma Therapeutics, Inc. Inhibiting mutant idh-1
FI3720442T3 (fi) 2018-05-16 2023-03-17 Forma Therapeutics Inc Mutantti idh-1:n inhibitio
US11013733B2 (en) * 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
CA2488635C (en) 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
JPWO2004043936A1 (ja) 2002-11-14 2006-03-09 協和醗酵工業株式会社 Ｐｌｋ阻害剤
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
JPWO2005095382A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
CN101679321B (zh) 2007-04-30 2012-10-03 普罗米蒂克生物科学公司 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
EP2509600B1 (en) * 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
CN102558049B (zh) * 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EA025183B1 (ru) 2011-09-27 2016-11-30 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
AU2012358317B2 (en) 2011-12-21 2017-12-14 Indiana University Research And Technology Corporation Anti-cancer compounds targeting Ral GTPases and methods of using the same
DK2800743T3 (en) * 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US9957235B2 (en) 2014-02-11 2018-05-01 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as mIDH1 inhibitors
US9771349B2 (en) 2014-09-19 2017-09-26 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6648116B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
JP6648115B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体
CA2971872C (en) 2014-12-22 2023-10-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant idh1 inhibitors useful for treating cancer
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
WO2017223202A1 (en) 2016-06-22 2017-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer
UA123640C2 (uk) 2016-12-16 2021-05-05 Елі Ліллі Енд Компані Сполука 7-фенілетиламіно-4н-піримідо[4,5-d][1,3]оксазин-2-ону (варіанти) як інгібітор мутантів idh1 та idh2

Also Published As

Publication number Publication date
HUE041460T2 (hu) 2019-05-28
CN111909130A (zh) 2020-11-10
MY197533A (en) 2023-06-21
AU2019283765A1 (en) 2020-01-16
EP3447050B1 (en) 2020-02-19
ME03776B (me) 2021-04-20
HRP20200666T1 (hr) 2020-07-24
ZA201702127B (en) 2019-06-26
DK3447050T3 (da) 2020-03-09
EP3194376A1 (en) 2017-07-26
NZ758641A (en) 2023-12-22
AU2021215141A1 (en) 2021-09-02
EP3447050A1 (en) 2019-02-27
CL2017000658A1 (es) 2017-12-22
US9834539B2 (en) 2017-12-05
IL282363A (en) 2021-06-30
EA201790657A8 (ru) 2018-02-28
FI3733662T3 (fi) 2023-08-09
PT3447050T (pt) 2020-09-17
US20230125739A1 (en) 2023-04-27
US20180312487A1 (en) 2018-11-01
US20190263778A1 (en) 2019-08-29
IL282363B (en) 2022-06-01
NZ730373A (en) 2019-11-29
HUE062424T2 (hu) 2023-11-28
US11498913B2 (en) 2022-11-15
ES2953347T3 (es) 2023-11-10
BR112017005238B1 (pt) 2023-01-17
ES2704897T3 (es) 2019-03-20
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
MX2019013203A (es) 2020-01-20
CO2017003241A2 (es) 2017-09-20
SG11201702194SA (en) 2017-04-27
MY176250A (en) 2020-07-24
US10550098B2 (en) 2020-02-04
CN117695280A (zh) 2024-03-15
AU2015317329B2 (en) 2019-10-31
MA40481A (fr) 2017-07-26
PL3447050T3 (pl) 2020-07-27
PL3194376T3 (pl) 2019-05-31
IL251163A0 (en) 2017-04-30
RS58184B1 (sr) 2019-03-29
CA2961817C (en) 2024-03-12
EP4257131A3 (en) 2024-01-10
ECSP17022933A (es) 2017-08-31
CN107001328B (zh) 2020-06-05
JP6648115B2 (ja) 2020-02-14
MX2017003404A (es) 2017-07-28
EP4257131A2 (en) 2023-10-11
SA517381129B1 (ar) 2021-04-26
AU2015317329A1 (en) 2017-04-27
US20170174658A1 (en) 2017-06-22
ZA201902446B (en) 2023-12-20
IL292608A (en) 2022-07-01
JP2017528487A (ja) 2017-09-28
SI3447050T1 (sl) 2020-08-31
EA201790657A1 (ru) 2017-08-31
KR102209667B1 (ko) 2021-01-29
US10414752B2 (en) 2019-09-17
PT3733662T (pt) 2023-08-18
LT3194376T (lt) 2019-02-25
CY1121149T1 (el) 2020-05-29
TWI686390B (zh) 2020-03-01
TW201617335A (zh) 2016-05-16
LT3447050T (lt) 2020-05-11
RS60140B1 (sr) 2020-05-29
AU2019283765B2 (en) 2021-05-13
EP3733662B1 (en) 2023-06-07
IL251163B (en) 2021-05-31
PH12017500517A1 (en) 2017-08-07
SI3194376T1 (sl) 2019-03-29
US20210078973A1 (en) 2021-03-18
US20240150319A1 (en) 2024-05-09
PL3733662T3 (pl) 2024-01-22
ES2790640T3 (es) 2020-10-28
CA2961817A1 (en) 2016-03-24
US10889567B2 (en) 2021-01-12
US20160083366A1 (en) 2016-03-24
EA034336B1 (ru) 2020-01-29
AU2021215141B2 (en) 2023-10-19
US20200223822A1 (en) 2020-07-16
PE20171056A1 (es) 2017-07-21
WO2016044789A1 (en) 2016-03-24
CN111909130B (zh) 2023-10-31
KR20170063742A (ko) 2017-06-08
PT3194376T (pt) 2019-02-04
MA53352A (fr) 2021-09-15
CN107001328A (zh) 2017-08-01
DK3194376T3 (en) 2019-01-21
EP3194376B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
BR112017005238A2 (pt) derivados de piridin-2(1h)-ona quinolinona como inibidores da isocitrato desidrogenase mutante
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
MX2017003626A (es) Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
MX2017003637A (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
MX370438B (es) Derivados quinolina como inhibidores smo.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201591689A1 (ru) НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3
UY33575A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
GT201300260A (es) Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri)
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
PH12016501349A1 (en) Hydroxy formamide derivatives and their use
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
BR112018006157A2 (pt) derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2015, OBSERVADAS AS CONDICOES LEGAIS